Prosensa is an innovative Dutch biopharmaceutical company focused on the discovery, development and commercialization of RNA-modulating therapeutics correcting gene expression in diseases with significant unmet need, in particular neuromuscular disorders. Prosensa’s current focus is on developing treatments for Duchenne muscular dystrophy (DMD), myotonic dystrophy and Huntington’s disease.
The company is based in Leiden, the Netherlands.
65 Gresham Street,
London, EC2V 7NQ
T: +44 (0)20 7457 2020
© 2017 Instinctif Partners – Registered in England & Wales No 1036926 / VAT No 245666930 | visit our global website instinctif.com